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Blood-Based Proteomic Biomarkers 
of Alzheimer’s Disease Pathology
Alison L. Baird* , Sarah Westwood and Simon Lovestone
Department of Psychiatry, University of Oxford, Oxford, UK
The complexity of Alzheimer’s disease (AD) and its long prodromal phase poses chal-
lenges for early diagnosis and yet allows for the possibility of the development of disease 
modifying treatments for secondary prevention. It is, therefore, of importance to develop 
biomarkers, in particular, in the preclinical or early phases that reflect the pathological 
characteristics of the disease and, moreover, could be of utility in triaging subjects 
for preventative therapeutic clinical trials. Much research has sought biomarkers for 
diagnostic purposes by comparing affected people to unaffected controls. However, 
given that AD pathology precedes disease onset, a pathology endophenotype design 
for biomarker discovery creates the opportunity for detection of much earlier markers of 
disease. Blood-based biomarkers potentially provide a minimally invasive option for this 
purpose and research in the field has adopted various “omics” approaches in order to 
achieve this. This review will, therefore, examine the current literature regarding blood-
based proteomic biomarkers of AD and its associated pathology.
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iNTRODUCTiON
Dementia is now a huge public health priority, with 115.4 million people worldwide estimated to be 
living with dementia by 2050 (1). These numbers are not only alarming on an individual level, but 
they are also unsustainable for our economy. Dementia costs the global economy US$604 billion, 
and like prevalence rates this figure is also set to increase with an 85% rise in costs estimated by the 
year 2030 (2).
The most common form of dementia is Alzheimer’s disease (AD), comprising approximately 
50–70% of the elderly dementia population. AD is characterized by multiple cognitive deficits, 
which cause significant impairment to social or occupational functioning. The disease typically has 
a gradual onset followed by continuing cognitive decline, with a mean duration of approximately 
8.5 years from the onset of clinical symptoms to the death of the patient (3).
Most clinical trials of potential therapeutic disease-modifying agents have involved individuals 
with clinically manifest dementia and have been relatively unsuccessful to date. Earlier stages of the 
disease are now being targeted, posing a challenge as it is difficult to detect individuals at this stage 
of AD; brain pathology is developing silently and cognitive symptoms if detectable are subtle. The 
underlying neuropathology characteristic of AD precedes symptom onset by many years, with the 
accumulation of amyloid-beta (Aβ) plaques believed to occur 15–20 years in advance of clinical 
manifestation of the disease (4), followed by the aggregation of abnormally phosphorylated tau in 
neurofibrillary tangles. A biological marker (biomarker) of these pathologic processes could serve as 
an indicator of disease presence, pathology, and progression. Moreover, they could have great utility 
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in drug development and clinical trials, in particular for use in 
patient stratification and cohort enrichment.
In this review, we will discuss various studies that have utilized 
proteomic-based approaches to discover blood-based biomark-
ers for early and ideally preclinical detection of AD pathological 
processes and their use in clinical trials. We performed literature 
searches on PubMed1 using the search terms detailed in Table 1. 
The literature included for review was supplemented with other 
known applicable papers that were not identified in the searches.
BiOMARKeRS FOR AD
Today, the biomarkers used most extensively in clinical trials 
for dementia and to some extent in clinical practice are struc-
tural magnetic resonance imaging (MRI), molecular imaging 
of amyloid deposition using positron emission tomography 
(PET), imaging of metabolism using fluoro-deoxy-d-glucose 
(FDG)-PET, and cerebrospinal fluid (CSF) measures of Aβ and 
tau. However, structural changes measured using MRI are most 
likely relatively late events in the disease course and PET imag-
ing is relatively expensive and limited in availability. Moreover, 
structural MRI and FDG-PET are not direct measures of the core 
pathological hallmarks of AD (Aβ and tau) and may, therefore, 
be relatively non-specific for AD in some cases (5) (Figure 1).
The most well-characterized and validated tissue fluid molec-
ular-based biomarker for AD is the decrease in Aβ and increase 
in tau and phospho-tau (pTau) observed in the CSF of people 
with AD, with a number of studies documenting discrimination 
of AD patients from healthy controls with good sensitivity and 
specificity, as reviewed by others (6). However, the clinical utility 
1 http://www.ncbi.nlm.nih.gov/pubmed
TABLe 1 | Search terms used for PubMed-based literature searches. Publications were filtered to include only studies in human species.
Search Search terms
Plasma Aβ and Tau as 
biomarkers of AD
[alzheimer*(Title/Abstract) OR dementia(Title/Abstract) AND AD(Title/Abstract)] AND [blood(Title/Abstract) OR plasma(Title/Abstract) 
OR serum(Title/Abstract)] AND [proteomic*(Title/Abstract) OR proteome(Title/Abstract) OR protein(Title/Abstract) OR proteins(Title/
Abstract)] AND [biomarker*(Title/Abstract) OR marker*(Title/Abstract)] AND [beta-amyloid(Title/Abstract) OR amyloid beta(Title/
Abstract) OR abeta(Title/Abstract) OR tau(Title/Abstract)]
Plasma biomarkers of AD 
(case–control studies)
[alzheimer*(Title/Abstract) OR dementia(Title/Abstract) AND AD(Title/Abstract)] AND [blood(Title/Abstract) OR plasma(Title/Abstract) 
OR serum(Title/Abstract)] AND [proteomic*(Title/Abstract) OR proteome(Title/Abstract) OR protein(Title/Abstract) OR proteins(Title/
Abstract)] AND [biomarker*(Title/Abstract) OR marker*(Title/Abstract)] AND [diagnos*(Title/Abstract) OR prognos*(Title/Abstract) OR 
progression(Title/Abstract)]
Plasma biomarkers of brain 
atrophy
[alzheimer*(Title/Abstract) OR dementia(Title/Abstract) AND AD(Title/Abstract)] AND [blood(Title/Abstract) OR plasma(Title/Abstract) 
OR serum(Title/Abstract)] AND [proteomic*(Title/Abstract) OR proteome(Title/Abstract) OR protein(Title/Abstract) OR proteins(Title/
Abstract)] AND [biomarker*(Title/Abstract) OR marker*(Title/Abstract)] AND [atrophy(Title/Abstract) OR brain volume(Title/Abstract) 
OR sMRI(Title/Abstract) OR structural magnetic resonance imaging(Title/Abstract) OR structural MRI(Title/Abstract)]
Plasma biomarkers of 
cognitive decline
[alzheimer*(Title/Abstract) OR dementia(Title/Abstract) AND AD(Title/Abstract)] AND [blood(Title/Abstract) OR plasma(Title/Abstract) 
OR serum(Title/Abstract)] AND [proteomic*(Title/Abstract) OR proteome(Title/Abstract) OR protein(Title/Abstract) OR proteins(Title/
Abstract)] AND [biomarker*(Title/Abstract) OR marker*(Title/Abstract)] AND [cognitive decline(Title/Abstract) OR cognition(Title/
Abstract) OR MMSE(Title/Abstract) OR ADAS(Title/Abstract) OR CDR(Title/Abstract)]
Plasma biomarkers of PET 
amyloid
[alzheimer*(Title/Abstract) OR dementia(Title/Abstract) AND AD(Title/Abstract)] AND [blood(Title/Abstract) OR plasma(Title/Abstract) 
OR serum(Title/Abstract)] AND [proteomic*(Title/Abstract) OR proteome(Title/Abstract) OR protein(Title/Abstract) OR proteins(Title/
Abstract)] AND [biomarker*(Title/Abstract) OR marker*(Title/Abstract)] AND [pib(Title/Abstract) OR Pittsburgh compound b(Title/
Abstract) OR florbetapir(Title/Abstract) OR flutemetamol(Title/Abstract) OR florbetaben(Title/Abstract) OR amyloid PET(Title/Abstract) 
OR brain amyloid(Title/Abstract)]
of this biomarker is limited by the relatively invasive nature of 
obtaining CSF (lumbar puncture), particularly from elderly 
individuals. This may limit its use in longitudinal studies or 
for clinical progression monitoring, for which repeated CSF 
measures would be required. Also, attention needs to be paid to 
standardization of measurement of these biomarkers, given that 
large inter-laboratory variation in the concentrations measured 
of these biomarkers are observed (7).
In a revised model of the temporal relationship between key 
biomarkers of AD pathology, Jack et al. (8) suggested that changes 
in CSF Aβ1–42 are the earliest detectable biomarker of AD pathol-
ogy, followed by the PET detection of changes in brain amyloid, 
changes in CSF tau levels, and finally MRI-based detection of 
hippocampal atrophy and FDG-PET measures of brain glucose 
metabolism, all of which occur prior to the emergence of clinical 
symptoms of the disease (8). This hypothesis is corroborated by 
the recent findings of a non-linear association between CSF Aβ1–42 
and florbetapir F-18 PET imaging of brain amyloid load at the 
extreme ends of the clinical scale, while strongest association 
is seen at the mid-range of clinically measured disease severity 
(9). These findings would suggest that the two measures could 
reflect different aspects of AD Aβ pathology, with PET ligands 
having poor affinity for diffuse plaques, which develop early. At 
this stage, the plaques retain Aβ and, hence, CSF measures of Aβ 
may be more sensitive than PET earlier on in the disease (9). It 
is, therefore, of importance to consider the sensitivity of these 
biomarkers in relation to the staging of disease when designing 
biomarker studies.
BLOOD-BASeD BiOMARKeRS
The minimally invasive and potentially inexpensive nature of tests 
using blood-based proteomic biomarkers make these approaches 
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practical to implement, allowing for repeated sampling in large 
cohorts, and, therefore, might have significant advantages over 
other biomarker modalities. However, the use of blood as a matrix 
for measurement of biomarkers has the inherent disadvantage of 
its complex composition and subsequently poses technical dif-
ficulties for biomarker detection.
The most challenging of many obstacles to developing blood-
based biomarkers is the massive dynamic range of proteins in 
blood, spanning up to 12 orders of magnitude (10). Furthermore, 
changes within the blood are often very small and reflect a wide 
range of both peripheral and central processes and, therefore, 
pinpointing AD-specific changes can be challenging. Separated 
by the blood–brain barrier the relationship between analytes 
found in the blood and changes in the brain is still uncertain. 
However, with aging and in AD, the blood–brain barrier is dis-
rupted resulting in increased permeability, and this is thought 
to be a relatively early event in the aging brain, worsening with 
increased cognitive impairment (11). Blood–brain barrier disrup-
tion should only strengthen the relationship between blood and 
brain, and as an early event this would support the possibility of 
detecting protein-based markers related to AD at the early stages 
of disease. Nevertheless, concentrations of most known potential 
biomarkers are considerably lower in the blood than reported in 
CSF. For example, Aβ peptide concentration is 100-fold lower in 
blood than in CSF (12). Additionally, highly abundant plasma 
proteins such as albumin and IgG may mask the presence of less 
abundant proteins that may serve as potential biomarkers.
TeCHNiQUeS FOR BLOOD-BASeD 
BiOMARKeR DiSCOveRY
The complexity of blood as a source of biomarkers is reflected 
in the limitations of various proteomic techniques that have 
been employed to investigate blood-based biomarkers for AD. 
FDG-PET imaging of 
brain metabolism
Relatively expensive 
and limited in 
availability
Cannot directly 
detect the core 
pathological features 
of AD (Aβ & tau)
Indicator of synaptic 
activity, neuronal 
function & neuronal 
metabolic activity
PET measures of 
brain amyloid
Relatively expensive 
and limited in 
availability
Specific surrogate 
measure of amyloid 
pathology in the 
brain
CSF measures of 
Aβ and Tau
CSF Aβ1-42 is the 
earliest detectable 
marker of AD 
pathology
Relatively invasive
Structural MRI of 
brain atrophy
Relatively late event 
(in comparison to 
CSF Aβ/tau and PET 
amyloid measures) 
Cannot directly 
detect the core 
pathological features 
of AD (Aβ & tau)
A measure of 
cerebral atrophy, a 
core feature of 
neurodegeneration
FiGURe 1 | Advantages (green boxes) and disadvantages (red boxes) of the biomarkers that are currently most widely used in clinical trials.
In the following section, we will provide a brief overview of 
some of the tools available for proteomic biomarker discovery in 
blood, including mass spectrometry (MS), immunocapture, and 
aptamer-based techniques. Each of these approaches has their 
advantages and disadvantages and to date studies have combined 
a number of these approaches in the discovery pipeline for iden-
tifying protein biomarkers related to AD.
Mass Spectrometry-Based Assays
For discovery-level proteomics, a key attribute required of the 
technique used is the ability to measure multiple targets simul-
taneously in a multiplexing manner. MS-based approaches have 
been widely used in this way and possess the inherent advantage 
of there being no requirement for prior knowledge of the proteins 
being identified, hence, allowing for unbiased hypothesis-free 
biomarker discovery. Moreover, to facilitate multiplexing capabili-
ties of MS-based protein quantification, approaches for labeling 
peptides or intact proteins have been developed, for example, the 
use of isobaric tags (13). This allows for the pooling of labeled sam-
ples for subsequent MS analysis, hence, increasing throughput. 
However, disadvantages of labeling may include increased com-
plexity in sample preparation compared to label-free approaches. 
Furthermore, quantitative information can only be provided for 
peptides that contain the labeled amino acid, limiting the quanti-
tative coverage of the sample to the labeled peptides alone.
However, the huge abundance of a select few proteins in 
plasma and serum limits the detection of lower molecular 
weight proteins by MS. In plasma and serum, albumin and the 
immunoglubulins (IgG, IgA, IgM, and IgD) represent 75% of the 
total protein weight, and 99% of these samples are constituted 
by only 22 different protein species (14). Fractionation of the 
sample is one of the approaches that can be taken to reduce this 
sample complexity (15). Immunoaffinity-based depletion of the 
most abundant proteins is another approach that can be used to 
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improve the detection of lower molecular weight proteins and the 
use of several different immunoaffinity depletion reagents have 
been documented (16–18). However, a disadvantage of depletion 
is the potential removal of lower molecular weight proteins, in 
addition to the high molecular weight targets for depletion. This 
is mainly an issue due to the binding nature of the protein targets 
for depletion, such as albumin, and, therefore, by removal of 
albumin, inadvertently albumin-bound lower molecular weight 
proteins may also be removed.
immunocapture-Based Assays
The gold standard for soluble protein quantification is ELISA. 
However, with the increasing need to measure multiple protein 
targets, with limited sample availability, multiplexing approaches 
for targeted and hypothesis-driven biomarker discovery are 
now increasingly being used. Two of the most widely used 
immunocapture-based multiplexing systems for this purpose are 
mesoscale discovery (MSD) and the Luminex xMAP technology.
Both MSD and Luminex xMAP technologies are similar to the 
“sandwich” ELISA in priniciple. However, in an MSD assay, the 
capture antibodies are coated on specific spot regions at the base 
of the wells of a microtiter plate. Capture antibodies for different 
targets can be coated on each of the different spots, thus, allowing 
for multiple protein targets to be captured simultaneously in a 
single sample. Electrochemiluminescence (SULFO-TAG) labels 
are then bound to the detection antibodies and upon electrical 
stimulation the SULFO-TAG labels emit light, which is used to 
quantify the amount of target protein present. Luminex xMAP 
assays, in contrast, use microsphere-based technology, which 
involves coating of the capture antibody to microspheres “beads” 
in suspension, and fluorescently labeled detection antibodies for 
detection and quantification. In this way, multiple beads may be 
coated with multiple capture antibodies for multiplexing protein 
measurements in a single sample. Whichever approach to multi-
plexed affinity capture is used, the method is dependent on the 
quality, binding characteristics, and batch stability of the primary 
(and indeed secondary) antibodies used.
Given the targeted nature of immunocapture-based 
assays, these approaches are not necessarily suitable for unbi-
ased hypothesis-free approaches for biomarker discovery. 
Furthermore, protein quantification by immunocapture methods 
will be epitope specific, and the quantitative values obtained will 
relate to the region of the protein recognized by the antibodies 
used within the assay. This is an important property to note when 
using immunocapture-based methods for replication of findings 
that may have been discovered on a different methodological 
platform, such as MS. Where failure to technically replicate data 
between platforms is observed, it could be due to differences 
in the region of the protein being recognized by the different 
assays. Platform and assay differences in protein quantification 
are, therefore, important points to consider when designing the 
pipeline for biomarker discovery and development.
Aptamer-Based Assays
Aptamer-based approaches also provide another approach for rela-
tive quantification of multiple proteins in a multiplexing manner. 
Aptamers are single-stranded oligonucleotides, which recognize 
and bind target proteins with high affinity and specificity. Using 
this technology, the protein signal is effectively transformed to a 
nucleotide signal for subsequent microarray-based quantification 
of the relative fluorescence levels. An example of this approach 
is the panel that Somalogic has developed, which measures over 
1300 analytes in a single sample2. Advantages of this technology 
are clearly the large and unrivaled number of protein targets that 
can be quantified simultaneously in a single sample, making this 
platform ideal for extensive proteomic analysis in samples of 
limited availability. However, proteins quantified in this way are 
limited to those for which aptamers have been designed just as 
immunoaffinity approaches are limited by antibody availability.
Each of the proteomic techniques described here have inher-
ent advantages and disadvantages for both hypothesis-generating 
and hypothesis-driven biomarker discovery. Furthermore, as 
described earlier, platform and assay differences may impact 
upon the ability to technically replicate findings at the discovery 
level, and should, therefore, be considered carefully when design-
ing biomarker studies.
BLOOD-BASeD MeASUReS OF Aβ AND 
TAU
In the CSF, Aβ42 (along with tau and pTau) shows good sensitivity 
and specificity for classifying AD patients from healthy controls 
(19). Given the success in developing CSF markers of Aβ and 
tau as biomarkers it is unsurprising, therefore, that parallel 
approaches have been attempted in blood.
Amyloid Beta
Amyloid-beta fragments are produced by β and γ-secretase 
metabolism of the protein APP. β-secretase cleavage of APP pro-
duces sAPPβ and a 99 amino acid membrane bound fragment, 
which upon subsequent γ-secretase cleavage produces various 
Aβ species (20). Of these Aβ species, Aβ40 is the most abundant, 
while the highly hydrophobic and insoluble Aβ42 is the principal 
component of amyloid plaques in the AD brain (21), although 
deposition of insoluble Aβ40 in plaques of the AD brain has also 
been observed (22).
To date, Aβ42 and Aβ40 are the predominant species that have 
been investigated in blood, however, as reviewed extensively by 
others (23, 24), the results of these studies have been somewhat 
contradictory. To illustrate this, a reduction in plasma levels 
of Aβ42 in mild cognitive impairment (MCI) and AD subjects 
compared to healthy controls has been shown (25), while no 
difference between AD and cognitively healthy controls in serum 
Aβ42 has also been reported by others (26).
In terms of disease progression, the results are equally con-
tradictory. An association of decreased plasma Aβ42 with more 
rapid cognitive decline in AD (27), progression from healthy to 
MCI (28), and conversion from MCI to AD (29) has been shown. 
Yet an opposite trend has also been reported, including increased 
Aβ42 with conversion from cognitively healthy to MCI (30) and 
elevated baseline plasma Aβ42 in participants who converted to 
2 www.somalogic.com
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AD versus participants who remained cognitively healthy over 
a 5-year period (31). Moreover, Mayeux et  al. showed that the 
increase in plasma Aβ42 was followed by a decrease in individuals 
with the onset of AD (31), a pattern that has been mirrored in 
healthy elderly participants, who demonstrated higher baseline 
plasma Aβ42 followed by greater reductions in plasma Aβ42 with 
cognitive decline (32).
The results of blood Aβ40 as an AD biomarker have also been 
conflicting and are perhaps not as promising as that of Aβ42. 
For example, both increased serum Aβ40 (26, 33) and decreased 
plasma Aβ40 (34) have been shown in AD versus healthy con-
trols. Reduced levels of plasma Aβ40 have also been associated 
with more rapid cognitive decline in AD (27), while no change 
in plasma Aβ40 between cognitively stable MCI and MCI to AD 
converters (29) or association with risk of developing dementia 
(35) have been observed.
Given the differing results of plasma Aβ42 and Aβ40 in relation 
to AD, it is not surprising that studies examining the potential of 
Aβ42/Aβ40 in blood as an AD marker have also been conflicting 
in their results. A number of studies have documented reduced 
plasma Aβ42/Aβ40 in association with AD-related parameters, 
including in MCI and AD subjects compared to healthy controls 
(25, 28), with progression from MCI to AD compared to cogni-
tively stable MCI (29) and with risk of developing MCI and AD 
(36). However, increased plasma Aβ42/Aβ40 has also been related 
to increased risk of developing AD (37).
Very recently, however, a much larger, prospective, commu-
nity-based study examined the levels of plasma Aβ42 and Aβ40 
in over 2000 dementia-free individuals, and followed these 
individuals for dementia/AD over an 8-year period (35). In this 
study, Chouraki et al., found that lower levels of plasma Aβ42 were 
associated with an increased risk of developing dementia, which 
given the size of the study may be one of the most promising 
plasma Aβ results to date.
The conflicting findings of different Aβ studies may perhaps 
suggest that the utility of plasma Aβ as a marker is quite disease-
stage specific, as postulated by Blasko et al. Their findings of a rela-
tionship of plasma Aβ with conversion from cognitively healthy 
to MCI, but not later in the disease course when participants 
convert from MCI to AD, would indicate that plasma Aβ may be 
more successful as a marker of pathology at the preclinical stages 
of disease. This theory would also be in line with why plasma Aβ42 
appears to perform as a marker of risk for developing dementia 
over an 8-year period, as documented by Chouraki et al.
Relationship Between Plasma and CSF Aβ
Given that CSF Aβ is normally cleared in blood (38), it could be 
hypothesized that a reduction in plasma Aβ42 would be observed 
following the decrease observed in CSF Aβ42 in late-onset AD (39). 
However, a number of studies have actually reported that CSF 
and plasma levels of Aβ42 and Aβ40 do not correlate well (40–42). 
There are several theories that could be proposed to explain this. 
First, the relationship between CSF and plasma levels of Aβ may 
only exist at specific stages of the disease, relating to the degree of 
aggregation of brain amyloid in plaques. Second, it is thought that 
plasma Aβ may have a causal role in the development of micro-
vascular dysfunction (43) and given the considerable incidence 
of cerebrovascular pathology in the AD brain (44), it has been 
proposed that this heterogeneity in pathology could also impact 
upon the levels of Aβ measured in blood.
Plasma Aβ and Neuropathology
The relationship between plasma Aβ and brain pathology is also 
not yet resolved. Levels of Aβ40 and Aβ42 1  year prior to post-
mortem brain tissue collection were not associated with frontal 
and temporal necortex Aβ40 and Aβ42 burden at post mortem 
(45). However, using PET measures of brain amyloid burden 
does suggest a relationship between plasma Aβ and brain amyloid 
load, with an association between reduced plasma Aβ42/Aβ40 and 
increased brain amyloid load being shown (28, 46, 47). Moreover, 
the ratio of the plasma proteins APP669-711 (cleavage product 
of the amyloid precursor protein) and Aβ42 was increased in 
individuals of high amyloid burden subjects and demonstrated 
good sensitivity and specificity (93 and 96% respectively) for 
discrimination of amyloid negative and positive subjects (48).
These findings indicate a potential relationship between plasma 
Aβ species and the neuropathology of AD, however, given the 
contradictory results of plasma Aβ as a marker of AD diagnosis 
and clinical progression, it is clear that further work is required in 
order to consolidate the findings. As mentioned earlier, potential 
theories for the variability in the blood Aβ study results have 
been suggested and include disease-heterogeneity effects upon 
Aβ levels, and a disease-stage-specific nature of Aβ as a marker, 
with perhaps Aβ acting as an effective marker of preclinical rather 
than established disease. While these are valid theories that likely 
are having an impact, they are not able to explain the full extent 
of variability between the different Aβ study findings.
Important additional issues that likely contribute to the 
variability observed between studies are the technical challenges 
encountered with measuring Aβ. First, Abdullah et al. reported 
high intra-subject differences in plasma Aβ measures, as assessed 
by ELISA in two to three separate blood samples retrieved within 
a 4-week period from each individual (26). This variation in part 
may be related to the performance of the Aβ assays, with perhaps 
variation in the measurements being introduced due to lack of 
sensitivity of these assays. However, it is worth noting that plasma 
Aβ exhibits a circadian rhythm in its levels (49) and, therefore, in 
order to use Aβ as a reliable marker, standardization in time of 
sampling will be required.
Second, it should be noted that many of the studies docu-
mented here have assessed plasma Aβ by immunocapture-based 
approaches, including commercially available and in-house 
optimized ELISAs (25–27, 29–31, 33, 36, 37, 42, 45, 46), luminex 
xMAP assays (25, 28, 35, 41, 42), and immunomagnetic reduc-
tion (IMR) assays (47). While ELISAs are the gold standard for 
protein quantification, it is possible that inter-study variation 
in the results could be introduced by the use of different assays, 
which use antibodies that recognize different epitopes of Aβ. In 
this situation, standardization in the assay used across studies so 
that blood Aβ measures were epitope specific would be advisable.
Another factor to be considered is the technical difficulties 
of measuring Aβ, which is present at low concentrations in 
blood and will readily bind other circulating proteins, such as 
albumin, lipoproteins, and complement factors (50). One way 
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to help overcome this issue might, therefore, be to develop an 
assay that can measure both free and cell/protein-bound Aβ. 
This is an approach that has been used to develop the AB test, 
which quantifies Aβ40 and Aβ42 peptides that are free in plasma 
and bound to other proteins in plasma and blood cells3. The AB 
test shows promise for measuring Aβ in an AD-based cohort 
(51). Chiu and colleagues also report quantification of plasma 
Aβ by another highly sensitive immunoassay, developed using 
a technology known as superconducting quantum interference 
device (SQUID) IMR assay. This technology is based on measur-
ing the magnetic signals produced from nanoparticles, bound to 
the target molecule of interest and is able to detect plasma Aβ 
levels as low as 1 pg/ml for Aβ40 and 10 pg/ml for Aβ42. This is 
lower than that of standard Aβ42 ELISAs, of which the lower limit 
of detection is generally around 50 pg/ml (52). Furthermore, the 
SQUID-IMR technology involves the use of iron-nanoparticles 
and it has been suggested that the iron-chelating effect may inhibit 
Aβ oligomerization, hence, reducing the issue of non-quantifiable 
Aβ oligomers (52). While the results of these new assays for Aβ 
are promising, validation of these assays in further larger and 
independent cohort studies is required.
Tau
To date the investigation of plasma tau-based measures and their 
utility as biomarkers for AD have also been limited, primarily due 
to tau being an axonal protein and, therefore, of low abundance in 
blood. Efforts have, therefore, been made to develop more sensi-
tive assays for detection and reliable quantification.
First, Henriksen et al. have reported measurement of specific 
tau fragments using an ELISA method. These assays quantified 
specific tau fragments in serum [ADAM10-generated fragment 
(Tau-A) and caspase-3-generated fragment (Tau-C)] (53, 54). 
Using this method, measures of serum Tau-A, Tau-C, and the 
Tau-A/Tau-C ratio were shown to be associated with cognitive 
change in AD, although no association of the serum tau fragments 
with CSF tau and pTau were observed (54). A second approach 
that has been reported for measuring tau utilizes a digital array-
based technology (55). This approach involves the isolation and 
detection of single enzyme molecules using femtolitre-sized 
reaction chambers, known as single-molecule arrays (SiMOA). 
This method facilitates the detection of the target at low concen-
trations by ensuring that the fluorophores are confined to small 
volumes and, hence, the concentration of fluorescently labeled 
target is high (56). Using this assay, elevated levels of plasma tau 
in AD in comparison to controls and MCI were shown, although 
a considerable overlap in the range of plasma tau across the 
diagnostic groups was also found (55). Moreover, no correlation 
between plasma and CSF tau levels were observed (55). Lastly, 
Chiu and colleagues reported quantification of plasma Tau by 
SQUID-IMR (as described earlier for detection of plasma Aβ) 
and showed an increase in plasma tau in MCI and AD, along with 
an association of plasma tau with clinical measures of cognition 
and regional brain volume (57). This is all early but promising 
work, and moving forward, as with blood Aβ measures, further 
3 www.araclon.com
replication of these findings in larger independent cohorts will be 
crucial for ascertaining the robustness of blood-based tau as an 
AD-related biomarker.
DiSCOveRY OF BLOOD-BASeD 
BiOMARKeRS OF AD USiNG A  
CASe–CONTROL STUDY DeSiGN
Since the blood–brain barrier damage that occurs in AD would 
facilitate movement of proteins between brain and blood (58), 
research has also focused upon the detection of other blood-based 
proteins, in addition to Aβ and tau, which may serve as markers 
for AD. Using both untargeted and candidate-based proteomic 
approaches and a case–control study design, a substantial num-
ber of proteins related to a diagnosis of AD or MCI have been 
identified (33, 59–95).
However, a panel of proteins rather than single protein candi-
dates may have greater sensitivity and specificity as a biomarker 
and may collectively better describe and characterize the disease 
and its pathology. A number of studies, including from our 
group, have, therefore, taken an approach of analyzing multi-
variate signatures for prediction of AD and/or MCI status, and 
have identified and evaluated different proteins that collectively 
demonstrate sensitivity and specificity for classifying AD and/or 
MCI to varying degrees (96–118).
Alzheimer’s disease biomarker studies premised upon a case–
control study design have been extensively reviewed by others 
(119, 120) and as would be expected, many of the candidates 
identified in these studies can be related to aspects of the disease 
pathology, for example, having roles in inflammatory and amy-
loidogenic processes.
These studies comparing established disease to non-disease 
or prediction of rate of progression in established disease are 
promising but of more value would be marker sets that detected 
preclinical or prodromal disease. One design enabling such 
discovery is the prediction of conversion from MCI by using his-
torical samples from research cohort participants with MCI com-
paring those who subsequently converted to dementia in a given 
time-frame to those who did not. One of the first such studies 
identified an 18 plasma protein signature that not only classified 
AD from control subjects with 90% accuracy but was also able to 
predict MCI patients who would convert to AD within 5 years 
(97). However, replication of the 18 protein biomarker panel in 
subsequent studies has so far been unsuccessful (103, 121, 122). 
Yang et al. also demonstrated prediction of MCI conversion to 
AD with 79% accuracy using a 60 protein biomarker set (123), 
while we identified a panel of 10 proteins that were shown to 
strongly associate with both the degree of disease severity and to 
predict MCI progression to AD with 87% accuracy (124). More 
recently, Apostolova et al. reported prediction of MCI progres-
sion to AD with 73% accuracy by plasma IL-6R combined with 
clinical measures and APOE genotype (125).
Although a number of plasma protein signatures of AD diag-
nosis, disease severity, and progression have been identified in 
discovery-based studies, a key concern for the field has been the 
lack of reproducibility of these results. As yet there has been no 
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single blood-based proteomic signature that can successfully dis-
tinguish between AD and MCI and cognitively healthy elderly in 
a reproducible manner. The reason for such non-reproducibility 
is unknown. It might be the inherent heterogeneity of the disease 
and the differences, therefore, between cohort studies. It might 
also be technical variability, including assay variation and sample 
collection and curation variation, or it might be that the find-
ings are in fact artifactual and there is no consistent proteomic 
signature to be found in blood. However, another reason for the 
failure to replicate might be the intrinsic limitation of case–con-
trol studies in a condition with such a long prodrome.
First, it is important to consider the heterogeneity of dementia 
and the extensive comorbidity and differential environmental 
exposure in the elderly. As well as multiple dementia conditions 
being hard to distinguish from each other, the AD group itself 
can be clinically heterogeneous as can MCI. Moreover, comorbid 
conditions are common in AD, and might not only alter the blood 
proteome directly but the associated polypharmacy prevalent in 
the elderly could also have an impact.
Second, case–control-based studies have inherent limitations 
when the target of discovery is in prodromal, or, worse, preclini-
cal disease. In the context of AD research, the goal of biomarker 
discovery is primarily to detect individuals harboring early 
pathological change but without manifest dementia, as these indi-
viduals might be the most likely to respond to disease modifying 
agents. And yet in case–control studies such individuals will be 
included in studies not in the “case” group but in the “control” 
group. Clearly, this study design is at best non-optimal and at 
worse, destined for failure.
The recent failure of phase III clinical trials of antibody 
therapies targeting amyloid pathology, in part probably due to 
the absence of brain amyloid pathology in a considerable propor-
tion of the participants (126, 127), highlights the important role 
biomarkers predictive of core AD neuropathology could play 
in recruitment to clinical trials. However, the inevitable screen 
failures using such approaches would be costly and increase the 
time to recruitment. Therefore, the development of a minimally 
invasive blood-based biomarker of AD pathology could have 
real utility as a first pass or triage marker, to identify potential 
participants more likely to harbor pathology and to reduce screen 
failure and, hence, facilitate trials conduct.
DiSCOveRY OF BLOOD-BASeD 
BiOMARKeRS OF AD PATHOLOGY USiNG 
AN eNDOPHeNOTYPe APPROACH
Endophenotype-based approaches for blood-based biomarker 
discovery have begun to be implemented and have utilized various 
AD-related measures to identify blood-based biomarkers reflec-
tive of disease activity and pathology, including at the preclinical 
stages. These studies have included endophenotypes defined by 
measures such as brain atrophy (structural MRI), rate of cogni-
tive decline, and brain amyloid β burden (Pittsburgh B (PiB) PET 
brain imaging), with change in PiB PET amyloid burden being 
the earliest event of these in the disease course. These studies have 
identified a number of different potential proteomic biomarkers 
(Tables 2 and 3).
Blood-Based Biomarkers of Brain Atrophy 
and Rate of Cognitive Decline
We began by focusing on endophenotype approaches using 
mostly the AddNeuroMed, a European multicentre study 
(143) and the neuroimaging substudy of the Baltimore 
Longitudinal Study for Aging (BLSA) (144). Two key pathol-
ogy endophenotypes were employed; structural neuroimag-
ing of atrophy as a proxy measure of in vivo pathology and 
rate of clinical progression (Table  2), which was calculated 
based on retrospective and prospective measures of cognitive 
decline.
In 2010, we published a study that utilized a 2DGE-MS/
MS-based approach to discover plasma protein markers of both of 
these outcome variables in AD (128). This work identified seven 
proteins (complement C3, γ-fibrinogen, serum albumin, comple-
ment factor-I, clusterin, α-1-microglobulin, and serum amyloid-
P) that were able to explain 34% of the variance in hippocampal 
volume in MCI and AD, and five proteins (complement compo-
nent C4a, complement C8, clusterin, ApoA1, and transthyretin) 
that were able to discriminate fast from slow progressing AD 
groups. These proteins were then selected for replication studies, 
including in an independent AD/MCI/control-based cohort, 
using an orthogonal immunoassay-based approach. In this study, 
we replicated the association of complement C3, complement 
factor-I, γ-fibrinogen and α-1-microglobulin with brain atrophy, 
and along with complement C3a, these five proteins were able to 
explain 35% of whole brain volume in AD (129). In a separate 
study, we also replicated the association of transthyretin with an 
increased rate of cognitive decline in AD (136).
However, the most promising candidate marker identified in 
this discovery study was the protein clusterin, which associated 
with both hippocampal atrophy and clinical progression (128). 
We also showed in this same study but in an independent (AD/
MCI/control) cohort, an association of clusterin with cognitive 
measures and with brain atrophy, specifically in the entorhinal 
cortex and with PiB PET measures of fibrillary amyloid burden 
in the entorhinal cortex of a non-demented elderly cohort (128). 
While very recently increased plasma clusterin levels have been 
associated with increased risk of conversion to AD and rate of 
cognitive decline in an independent study (145). These findings 
indicate that changes in plasma clusterin may be an early event 
in the disease course, which occurs with amyloid deposition 
but prior (or without) onset of clinical symptoms. Moreover, 
in this same study, we demonstrated colocalization of clusterin 
with Aβ in plaques in the brains of a transgenic mouse model 
of AD (TASTPM) (128), thus, adding further support to the 
theory that clusterin may be implicated in amyloid formation 
and clearance (146).
Adding weight to our hypothesis that changes in plasma 
clusterin were an early event, increased levels of plasma clusterin 
in association with slower rates of brain atrophy in MCI were 
demonstrated (131). However, to the contrary, Song et al. demon-
strated an association of increased plasma clusterin with reduced 
white matter volume in MCI/cognitively healthy elderly over a 
2-year period (130). These findings are somewhat contradictory, 
and could be explained in part by the evidence for clusterin 
having both neuroprotective and pro-amyloidegenic properties, 
TABLe 2 | Summary of the significant findings of studies examining plasma protein markers of brain atrophy and rate of cognitive decline.
Proteins Outcome variables (subjects) Analytical platform Study
endophenotype: structural MRi measures of brain atrophy
C3, FGG, albumin, CFI, clusterin, A1M and SAP Hippocampal atrophy (AD and MCI) 2DGE LC-MS/MS (128)
C3, C3a, CFI, FGG, and A1M Whole brain volume (AD) ELISA and western blots (129)
ApoB/ApoA1a, ApoC3b, ApoEb, and Clusterinb,c Hippocampal volumea, gray matter volumeb, and  
white matter volumec (MCI and  
non-demented elderly)
Luminex xMAP (Myriad RBM) (130)
Clusterin Rate of brain atrophy (multiple brain regions in MCI) ELISA (131)
IL-1rad IL-6d, IL-10d, IL-13e, and TNF-αf Ventricular volumed, entorhinal cortex volumee, and 
whole brain volumef (AD)
Luminex xMAP (132)
MIP1α, IGFBP2, CgA, and cortisol SPARE-AD measures of brain atrophy (AD, MCI, and 
non-demented elderly)
Luminex xMAP (Myriad RBM) (133)
RANTESg, NSEg,h, TTRg,h, clustering, A1ATh, ApoC3h, 
ApoA1h, ApoEh, BDNF h and Aβ40h
Atrophy in multiple brain regions (MCIg and ADh) Luminex xMAP (124)
PPY, fetuin B, PSA-ACT, and ChkT Entorhinal cortex and hippocampal volume (AD, MCI, 
and non-demented elderly)
SOMAscan (134)
ApoE Hippocampal volume (MCI, non demented elderly) Luminex xMAP (Myriad RBM) (135)
endophenotype: rate of cognitive decline
C4a, C8, clusterin, ApoA1, and TTR Rate of cognitive decline (AD) 2DGE LC-MS/MS (128)
ApoA1, ApoA2, ApoH, and ApoB/ApoA1 ratio Risk of cognitive decline (non-demented elderly) Luminex xMAP (Myriad RBM (130)
TTR Rate of cognitive decline (AD) ELISA (136)
IL-4, IL-10, G-CSF, IL-2, IFN-γ, and PDGF Rate of cognitive decline (AD) Luminex xMAP (132)
NCAM, sRAGE, and ICAM Rate of cognitive decline (AD) Luminex xMAP (124)
Clusterin and NAP2 Rate of cognitive decline (AD) SOMAscan (134)
C3, complement C3; FGG, γ-fibrinogen; CF1, complement factor-I; A1M, α-1-microglobulin; SAP, serum amyloid-P; C3a, complement C3a; ApoB, apolipoprotein B; ApoA1, 
apolipoprotein A1; ApoC3, apolipoprotein C3; ApoE, apolipoprotein E; ApoC4, apolipoprotein C4; IL-1ra, interleukin 1 receptor antagonist; IL-6, interleukin-6; IL-10, interleukin-10; 
IL-13, interleukin-13; TNF-α, tumor necrosis factor alpha; MIP1α, macrophage inhibitory protein 1α; IGFBP2, insulin-like growth factor binding protein 2; CgA, chromogranin 
A; RANTES, regulated on activation normal T cell expressed and secreted; NSE, neuron-specific enolase; TTR, transthyretin; A1AT, alpha 1 antitrypsin; BDNF, brain derived 
neurotrophic factor; Aβ40, amyloid beta 1-40; PPY, pancreatic polypeptide; PSA-ACT, prostate-specific antigen complexed to α1-antichymotrypsin; Chk2, serine/threonine-protein 
kinase Chk2; C4a, complement component C4a; C8, complement C8; ApoA2, apolipoprotein A-2; ApoH, apolipoprotein-H; IL-4, interleukin-4; G-CSF, granulocyte-colony-
stimulating factor; IL-2, interleukin-2; IFN-γ, interferon-gamma; PDGF, platelet-derived growth factor; NCAM, neural cell adhesion molecule; sRAGE, soluble receptor for advanced 
glycation end products; ICAM, intercellular adhesion molecule; NAP2, nucleosome assembly protein 2.
November 2015 | Volume 6 | Article 2368
Baird et al. Alzheimer’s Disease Pathology: Blood-Based Biomarkers
Frontiers in Neurology | www.frontiersin.org
the evidence for an inflammatory component in AD pathol-
ogy (159, 160). We observed five proteins that were associated 
with brain atrophy measures (IL-1ra, IL-6, IL-10, TNF-α, 
and IL-13) and six proteins that were associated with rate of 
cognitive decline in AD (IL-4, IL-10, G-CSF, IL-2, IFN-γ, and 
PDGF) (132). Of note was the association of IL-10 with both 
brain atrophy and rate of cognitive decline, adding further 
confidence to the finding of its association with AD-related 
endophenotypes (132). Toledo et al. also published findings 
of inflammatory proteins (macrophage inflammatory protein 
1 alpha, chromogranin A) along with proteins implicated in 
the stress response (cortisol) and insulin response (insulin-
like growth factor binding protein 2) as markers of brain 
atrophy (133).
Following the identification of various plasma proteins related 
to AD and proxy measures of disease activity (neuroimaging 
measured of brain atrophy and clinical measures of cognitive 
decline), we next sought to validate the most promising and 
disease-relevant protein markers. To do this, we used multiplex 
bead assays to measure candidate proteins in a larger (N > 1000) 
cohort of AD/MCI/control participants (124). Interestingly, we 
found that different sets of proteins were associated with brain 
atrophy in MCI compared to AD, indicating that these markers 
are disease-phase specific, and the strongest associations with 
brain atrophy were observed for clusterin in the MCI group and 
ApoE in the AD group (124). Furthermore, we identified three 
proteins NCAM, sRAGE, and ICAM as being associated with rate 
of cognitive decline and we, therefore, hypothesized that these 
markers may be predictive of conversion from MCI to AD. When 
we tested this, we found that there were a panel of 10 proteins 
(transthyretin, clusterin, cystatin C, A1AcidG, ICAM1, comple-
ment component C4, PEDF, A1AT, RANTES, and ApoC3) along 
with APOE genotype, which were able to predict MCI conversion 
to AD with 87% accuracy, 85% sensitivity, and 88% specificity, as 
described earlier (124).
Blood-Based Biomarkers of Brain Amyloid 
Burden
Blood-based biomarkers of neocortical Aβ (extracellular 
β-amyloid) burden (NAB) as measured by PET brain imaging 
have also been sought (Table  3). These studies have used the 
Australian Imaging, Biomarker and Lifestyle Flagship Study of 
Ageing (AIBL) (161), the ADNI4, and the BLSA (144) for the 
purpose of finding plasma proteomic markers of brain amyloid 
burden.
The first study we carried out used the BLSA study to discover 
plasma proteins that were associated with NAB in non-demented 
elderly individuals (137). Using a 2DGE-MS/MS-based approach, 
this study identified six proteins (ApoE, Complement C3, 
Albumin, Plasminogen, Haptoglobin and IgG C chain region) 
that discriminated “high” from “low” PiB PET brain amyloid 
burden subjects in discovery-based studies, and a further associa-
tion of ApoE with amyloid burden in the medial temporal lobe in 
an independent validation study (137).
4 www.adni-info.org
TABLe 3 | Summary of the significant findings of studies examining plasma protein markers of PeT amyloid.
Protein(s) Outcome variable (subjects) Analytical platform Study
Clusterin PiB PET amyloid (non-demented elderly) ELISA (128)
ApoE, C3, albumin, plasminogen, haptoglobin and IgG C chain region PiB PET amyloid (non-demented elderly) 2DGE LC-MS/MS (137)
C-peptide, fibrinogen, A1AT, PPY, C3, vitronectin, cortisol, AXL receptor 
kinase, IL-3, IL-13, MMP9, ApoE, and IgE (this panel of proteins combined 
with covariates predicts amyloid positive subjects with 92 and 55%  
sensitivity and specificity, respectively)
PiB PET amyloid (AD, MCI, and non-
demented elderly)
Luminex xMAP 
(Myriad RBM)
(138)
Aβ1–42, CXCL-13, IL-17, IgM-1, PPY, and VCAM-1 (this panel of proteins 
with age, APOE genotype, and CDR sum of boxes predicts NAB with 79  
and 76% sensitivity and specificity, respectively)
PiB PET amyloid (AD, MCI, and non-
demented elderly)
Luminex xMAP 
(Myriad RBM)
(139)
A2M, CFHR1, and FGG. (FGG in combination with age predicts NAB with  
59 and 78% sensitivity and specificity, respectively)
PiB PET amyloid (AD, MCI, and non-
demented elderly)
TMT LC-MS/MS (140)
IL-6R, ApoE, and clusterin (in combination with clinical measures: trails B, 
AVLT, MMSE, education, APOE genotype and mean hippocampal volume 
predicts NAB with 79 and 83% sensitivity and specificity)
CSF Aβ and PiB PET amyloid (MCI) Luminex xMAP 
(Myriad RBM)
(125)
BDNF PiB PET amyloid (AD, MCI and non-
demented elderly)
Luminex xMAP 
(Myriad RBM)
(141)
PPY and IgM* PiB PET amyloid (AD, MCI, and non-
demented elderly, *non-demented elderly 
only)
SOMAscan (142)
ApoE, apolipoprotein E; C3, complement C3; A1AT, alpha 1 antitrypsin; PPY, pancreatic polypeptide; IL-3, interleukin-3; IL-13, interleukin-13; MMP9, matrix metalloproteinase-9 
total; ApoE, apolipoprotein E; IgE, immunoglobulin E; CKCL-13, chemokine ligand 13; IL-17, interleukin-17; IgM-1, immunoglobulin M; VCAM-1, vascular cell adhesion protein; A2M, 
alpha 2 macroglobulin; CFHR1, CFH-related protein 1; FGG, fibrinogen gamma chain; NAB, neocortical amyloid burden.
*non demented elderly only.
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dependent on its concentration relative to Aβ. Clusterin is impli-
cated in Aβ aggregation and clearance (146–151) and at high 
concentrations, clusterin binds Aβ, thus, preventing its aggrega-
tion. Yet when Aβ levels are high, clusterin instead is incorpo-
rated with amyloid in insoluble aggregates (148). Furthermore, 
clusterin possesses neurotoxic properties, as demonstrated by its 
involvement in non-canonical wnt signaling (the wnt–PCP–JNK 
pathway), which mediates Aβ toxicity (152). It could, therefore, be 
postulated that clusterin is playing different roles in these studies 
that demonstrate opposing relationships of plasma clusterin with 
brain atrophy. Nonetheless, these studies add further evidence 
for the role of clusterin in AD pathology. It is also worth noting 
that evidence for clusterin being implicated in AD pathology has 
also been provided on the genetic level, with an association of the 
variant rs11136000 in the clusterin gene with AD risk (153, 154), 
increased rates of cognitive decline at the pre-symptomatic stages 
of the disease (155) and brain volume and structure (volumetric 
expansion and lateral ventricle surface morphology) in AD, MCI, 
and elderly control subjects (156).
To date, clusterin is likely to be the most promising potential 
biomarker of AD-related phenotypes that we have identified in 
our studies, as supported by an association on the proteomic level 
with both clinical and neuroimaging measures of AD pathology, 
on the genetic level with AD risk and on a mechanistic level with 
amyloid function and processing.
Following the identification of clusterin using a dual endophe-
notype-based approach founded upon both brain atrophy and 
cognitive decline measures, we sought to extend this approach 
further to find biomarkers of these endophenotypes using dif-
ferent proteomic methods, which may be more sensitive for 
detection of alternative groups of proteins. One such study was 
reported by Sattlecker et al. who utilized the SOMAscan technol-
ogy for plasma protein biomarker discovery in a cohort of AD, 
MCI, and controls. The strongest findings of this study included 
an association of clusterin with cognitive decline, replicating the 
findings of Thambisetty et  al. (128), along with an association 
of fetuin B and pancreatic polypeptide with brain atrophy, and 
an association of pancreatic polypeptide and PSA-ACT with a 
diagnosis of AD (134).
In addition to hypothesis generating discovery approaches, 
targeted hypothesis-driven approaches have also been successful 
in identifying potential biomarkers of brain atrophy and cognitive 
decline. For example, the apolipoprotein family is widely impli-
cated in neurodegeneration (157, 158) and in a targeted study, 
Song et al. showed a negative correlation of plasma clusterin and 
ApoE with gray matter volume and an association of ApoA1, 
ApoA2, ApoH, and the ApoB/ApoA1 ratio with risk of cognitive 
decline in cognitively normal individuals (130). As these proteins 
are associated with pathology-related outcomes at the preclinical 
stage of disease, this would suggest that the apolipoproteins may 
be markers in an early phase of the disease pathogenesis. More 
recently, Teng et al. also showed an association of plasma ApoE 
levels with hippocampal volume in a cohort of AD, MCI, and 
control included in the Alzheimer’s disease neuroimaging initia-
tive (ADNI) cohort (135).
We have also taken a targeted approach to examine the 
biomarker potential of inflammatory proteins (132), given 
the evidence for an inflammatory component in AD pathol-
ogy (159, 160). We observed five proteins that were associated 
with brain atrophy measures (IL-1ra, IL-6, IL-10, TNF-α, 
and IL-13) and six proteins that were associated with rate of 
cognitive decline in AD (IL-4, IL-10, G-CSF, IL-2, IFN-γ, and 
PDGF) (132). Of note was the association of IL-10 with both 
brain atrophy and rate of cognitive decline, adding further 
confidence to the finding of its association with AD-related 
endophenotypes (132). Toledo et al. also published findings 
of inflammatory proteins (macrophage inflammatory protein 
1 alpha, chromogranin A) along with proteins implicated in 
the stress response (cortisol) and insulin response (insulin-
like growth factor binding protein 2) as markers of brain 
atrophy (133).
Following the identification of various plasma proteins related 
to AD and proxy measures of disease activity (neuroimaging 
measured of brain atrophy and clinical measures of cognitive 
decline), we next sought to validate the most promising and 
disease-relevant protein markers. To do this, we used multiplex 
bead assays to measure candidate proteins in a larger (N > 1000) 
cohort of AD/MCI/control participants (124). Interestingly, we 
found that different sets of proteins were associated with brain 
atrophy in MCI compared to AD, indicating that these markers 
are disease-phase specific, and the strongest associations with 
brain atrophy were observed for clusterin in the MCI group and 
ApoE in the AD group (124). Furthermore, we identified three 
proteins NCAM, sRAGE, and ICAM as being associated with rate 
of cognitive decline and we, therefore, hypothesized that these 
markers may be predictive of conversion from MCI to AD. When 
we tested this, we found that there were a panel of 10 proteins 
(transthyretin, clusterin, cystatin C, A1AcidG, ICAM1, comple-
ment component C4, PEDF, A1AT, RANTES, and ApoC3) along 
with APOE genotype, which were able to predict MCI conversion 
to AD with 87% accuracy, 85% sensitivity, and 88% specificity, as 
described earlier (124).
Blood-Based Biomarkers of Brain Amyloid 
Burden
Blood-based biomarkers of neocortical Aβ (extracellular 
β-amyloid) burden (NAB) as measured by PET brain imaging 
have also been sought (Table  3). These studies have used the 
Australian Imaging, Biomarker and Lifestyle Flagship Study of 
Ageing (AIBL) (161), the ADNI4, and the BLSA (144) for the 
purpose of finding plasma proteomic markers of brain amyloid 
burden.
The first study we carried out used the BLSA study to discover 
plasma proteins that were associated with NAB in non-demented 
elderly individuals (137). Using a 2DGE-MS/MS-based approach, 
this study identified six proteins (ApoE, Complement C3, 
Albumin, Plasminogen, Haptoglobin and IgG C chain region) 
that discriminated “high” from “low” PiB PET brain amyloid 
burden subjects in discovery-based studies, and a further associa-
tion of ApoE with amyloid burden in the medial temporal lobe in 
an independent validation study (137).
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TABLe 3 | Summary of the significant findings of studies examining plasma protein markers of PeT amyloid.
Protein(s) Outcome variable (subjects) Analytical platform Study
Clusterin PiB PET amyloid (non-demented elderly) ELISA (128)
ApoE, C3, albumin, plasminogen, haptoglobin and IgG C chain region PiB PET amyloid (non-demented elderly) 2DGE LC-MS/MS (137)
C-peptide, fibrinogen, A1AT, PPY, C3, vitronectin, cortisol, AXL receptor 
kinase, IL-3, IL-13, MMP9, ApoE, and IgE (this panel of proteins combined 
with covariates predicts amyloid positive subjects with 92 and 55%  
sensitivity and specificity, respectively)
PiB PET amyloid (AD, MCI, and non-
demented elderly)
Luminex xMAP 
(Myriad RBM)
(138)
Aβ1–42, CXCL-13, IL-17, IgM-1, PPY, and VCAM-1 (this panel of proteins 
with age, APOE genotype, and CDR sum of boxes predicts NAB with 79  
and 76% sensitivity and specificity, respectively)
PiB PET amyloid (AD, MCI, and non-
demented elderly)
Luminex xMAP 
(Myriad RBM)
(139)
A2M, CFHR1, and FGG. (FGG in combination with age predicts NAB with  
59 and 78% sensitivity and specificity, respectively)
PiB PET amyloid (AD, MCI, and non-
demented elderly)
TMT LC-MS/MS (140)
IL-6R, ApoE, and clusterin (in combination with clinical measures: trails B, 
AVLT, MMSE, education, APOE genotype and mean hippocampal volume 
predicts NAB with 79 and 83% sensitivity and specificity)
CSF Aβ and PiB PET amyloid (MCI) Luminex xMAP 
(Myriad RBM)
(125)
BDNF PiB PET amyloid (AD, MCI and non-
demented elderly)
Luminex xMAP 
(Myriad RBM)
(141)
PPY and IgM* PiB PET amyloid (AD, MCI, and non-
demented elderly, *non-demented elderly 
only)
SOMAscan (142)
ApoE, apolipoprotein E; C3, complement C3; A1AT, alpha 1 antitrypsin; PPY, pancreatic polypeptide; IL-3, interleukin-3; IL-13, interleukin-13; MMP9, matrix metalloproteinase-9 
total; ApoE, apolipoprotein E; IgE, immunoglobulin E; CKCL-13, chemokine ligand 13; IL-17, interleukin-17; IgM-1, immunoglobulin M; VCAM-1, vascular cell adhesion protein; A2M, 
alpha 2 macroglobulin; CFHR1, CFH-related protein 1; FGG, fibrinogen gamma chain; NAB, neocortical amyloid burden.
*non demented elderly only.
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Following this, we carried out a separate study to examine the 
association of plasma proteins with NAB in AD, MCI, and con-
trol subjects included in the ADNI5 (138). Plasma proteins were 
measured by the Myriad Rules-Based Medicine (RBM) panel 
using commercially available multiplexed luminex assays. This 
work identified 13 plasma proteins (c-peptide, fibrinogen, A1AT, 
pancreatic polypeptide, complement C3, vitronectin, cortisol, 
AXL receptor kinase, IL-3, IL-13, matrix metalloproteinase-9 
total, ApoE, and IgE), which in combination with covariates were 
able to discriminate PiB-positive from PiB-negative individuals 
with 92 and 55% sensitivity and specificity, respectively (138).
Shortly after this, Burnham et al. published a study that again 
utilized the RBM panel for identifying plasma proteins predictive 
of NAB in an AD, MCI, and control-based population; however, 
this study utilized the AIBL study for discovery, followed by 
validation of potential biomarkers of NAB in the ADNI (139). 
In summary, Burnham et al. identified six plasma proteins (Aβ42, 
chemokine ligand 13, IL-17, IgM-1, pancreatic polypeptide and 
VCAM-1) that contributed to a biomarker signature that was able 
to predict NAB with 79 and 76% sensitivity and specificity in the 
ADNI-based validation cohort (139).
More recently, a study carried out in an ADNI-based MCI 
cohort revealed that plasma IL-6 receptor, clusterin, and ApoE 
levels coupled with a number of clinical and demographic 
measures, APOE genotype and mean hippocampal volume, 
achieved 79 and 83% sensitivity and specificity for prediction of 
NAB (125). Hwang et al. also reported an association of reduced 
plasma BDNF levels with increased regional measures of NAB in 
an ADNI cohort (141).
We also recently reported the results of an LC-MS/MS-based 
approach for the discovery of plasma protein biomarkers of NAB 
in AD, MCI, and healthy controls enrolled in the AIBL study 
(140). Using this approach, a number of plasma proteins were 
shown to be significantly associated with NAB, including A2M, 
CFH-related protein 1, and γ-fibrinogen. Moreover, the associa-
tion of γ-fibrinogen in combination with age was found to predict 
NAB with 59 and 78% sensitivity and specificity, respectively 
(140).
Although the exact protein biomarker panels identified by 
these studies for prediction of NAB differs between the studies, 
it is of note that there are some commonalities in the proteins 
included in these biomarker panels, including ApoE (125, 137, 
138), complement C3 (137, 138), and pancreatic polypeptide 
(138, 139). A recent study, therefore, sought to replicate these 
findings in an independent cohort of AD, MCI, and control 
subjects in the AIBL study (142). This work replicated an associa-
tion of two proteins with NAB; pancreatic polypeptide across the 
cohort of AD, MCI, and cognitively healthy elderly, and IgM in 
the cognitively healthy elderly group, while the association of the 
other protein candidates with NAB was not replicated (142). This 
lack of replication between studies is disappointing; however, it is 
quite possible that this could be in part due to technical platform 
differences, as the discovery studies used both MS (137, 140) and 
immunocapture-based approaches (125, 138, 139, 141), while 
5 adni.loni.ucla.edu
replication was sought using the SOMAscan platform (142). As 
mentioned earlier, platform and assay differences may provide 
differing quantitative proteomic results, given that there are 
key differences in the nature of the protein being measured by 
these techniques. MS approaches measure denatured protein in 
a peptide-specific manner, while immunocapture-based assays 
use antibodies for epitope-specific native protein measures. The 
SOMAscan platform also measures native protein, but by binding 
of an aptamer to a tertiary structure-specific epitope. Therefore, 
differences in the region and confirmation of the protein target 
being measured by these different techniques may result in vary-
ing quantitative results.
These various studies utilizing an AD pathology endophe-
notype-based approach for biomarker discovery show promise 
in identifying biomarkers reflective of core AD pathology and 
disease activity. However, it is important to note that there are 
some issues surrounding the approach of predicating blood-
based biomarker discovery on PET amyloid measures. First, 
PiB PET detects insoluble fibrillary but not insoluble oligomeric 
Aβ, which are known to possess neurotoxic and synaptotoxic 
properties (162). Therefore, blood-based biomarkers of PiB PET 
amyloid may not be the most relevant markers of brain amyloid 
pathology. Second, it is possible that the relationship of plasma 
proteins with PiB PET amyloid measures could be specific to 
the technical aspects of the PET imaging technique used. For 
example, variability in the amyloid measure could be introduced 
by the use of alternative radiotracers or alternative methods of 
PET data analysis.
Therefore, in order to assess the reproducibility and robustness 
of plasma proteins biomarkers of amyloid (as indicated by PiB 
PET), it will be essential to perform replication and validation 
studies examining their association with brain amyloid burden 
(1) in larger independent cohorts, (2) using orthogonal technical 
platforms for biomarker quantification, and (3) using alternative 
measures indicative of amyloid (for example, alternative PET 
amyloid radiotracers and CSF Aβ).
Other Potential endophenotype 
Approaches
While endophenotype-based designs founded upon rates of 
cognitive decline, brain atrophy, and brain amyloid burden show 
promise, there are further measures of AD and other aspects of 
core AD neuropathology that warrant investigation as potential 
endophenotypes for biomarker discovery. FDG-PET measures 
cerebral metabolic glucose utilization rate and serves as an 
indicator of synaptic activity, neuronal function, and neuronal 
metabolic activity (163). FDG-PET has been reported to have 
an average diagnostic accuracy of 93% (96% sensitivity and 90% 
specificity) for differentiating AD from cognitively healthy elderly 
subjects (164), and can discriminate between different dementia-
types with around 94% accuracy (165). Using FDG-PET as 
an endophenotype of pathology for blood-based biomarker 
discovery could, therefore, aid in the development of biomarkers 
relating to synaptic and neuronal function, and the prodromal 
stage of disease, given that hypometabolism is known to occur 
in amnestic MCI (165, 166). Moreover, glucose metabolism 
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is thought to be more closely associated with certain memory, 
language, and visuospatial clinical variants of AD than measures 
of Aβ deposition and so plasma protein biomarkers of FDG-PET 
cerebral glucose metabolism could be of utility in detecting these 
clinical aspects of the disease (167).
With the development of tau imaging comes the opportunity 
to investigate blood-based biomarkers related specifically to 
brain tau pathology, which could obviously be of potential utility 
beyond AD and for tauopathies such as fronto-temporal demen-
tia. The development of tau imaging has been challenging due to 
the deposition of tau protein being intracellular, which impacts 
upon radiotracer binding and image contrast (168). However, 
current research to develop various tau brain imaging tracers is 
underway, including the tracers 18F-THK523, [F-18]-T807, and 
[F-18]-T808 (169–171). PET imaging of tau could, therefore, pro-
vide another endophenotype parameter for the design of studies 
that seek to uncover peripheral proteomic biomarkers relating 
specifically to tau pathology in the brain.
Moreover, other types of biomarkers detectable in the blood 
show promise as potential markers of AD, including, for example, 
metabolomic (172–175) and transcriptomic-based markers (176, 
177). Further research to examine how these markers may be 
related to pathology endophenotypes and the potential of com-
bining these markers as a multimodal signature of AD pathology 
will be important.
CONCLUSiON
Much research has sought blood-based proteomic biomarkers 
that may have diagnostic utility in discriminating AD cases 
from control, with limited success in identifying a reproducible 
signature of diagnostic or trials utility.
An alternative approach, which we have increasingly employed 
is using surrogates for disease activity – endophenotypes – such 
as cerebral atrophy imaging or molecular markers of amyloid 
pathology and rate of decline. Such an approach yields different 
but overlapping panels of markers. It is, therefore, possible that 
such markers predicated on pathological processes might be 
more reproducible and ultimately of more utility in diagnostic, 
prognostic, predictive, and other utilities especially in the context 
of clinical trials.
However, it seems intrinsically unlikely to us that a blood-
based biomarker would replace relatively specific and reliable 
markers such as molecular markers in CSF or PET imaging mark-
ers that are more proximal to the disease state. Rather, we predict 
that blood-based biomarkers might be less specific but possibly 
more sensitive and certainly more readily conducted repeatedly 
in the context of large-scale, community-based studies and where 
repeated measures to track change is required. This then raises 
the prospect of what might be termed the biomarker funnel, 
a series of tests and investigations starting with the minimally 
invasive, highly sensitive, poorly specific marker set leading 
toward a technologically demanding or invasive test that is highly 
specific. This would be a blood test triage or selection process 
for CSF or PET tests in effect. Such a funnel is commonplace in 
medicine – fasting glucose before a glucose tolerance test, mam-
mography before biopsy are examples, but there are many others. 
A biomarker funnel with blood-based markers as an early step 
toward a pathological diagnosis in life would be a very substantial 
step forward and maybe an essential step before clinical trials can 
be both effective and achievable.
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